A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties
We have been exploring the potential of 5-HT2B antagonists as a therapy for chronic heart failure. To assess the potential of this therapeutic approach, we sought compounds possessing the following attributes: (a) potent and selective antagonis